Gland Pharma shares rise 5% on receiving US FDA approval for vitamin K deficiency injectable

Gland Pharma shares rose after receiving FDA approval for phytonadione injectable emulsion, a product used for coagulation disorders. Despite a 15.7% YoY decline in Q2 FY25 net profit, revenue increased by 2.4%. The stock has a target price of Rs 1,813, with a 'Hold' rating from analysts. Technically, the stock’s RSI stands at 51.5.